Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Safety Study For Prevenar 13 Among Chinese Children

Completed

Conditions: Seizures
Apnea
Fever
Urticaria and Angioedema

First Posted Date: 2018-09-04

Last Posted Date: 2021-08-27

Lead Sponsor: Pfizer

Target Recruit Count: 21240

Registration Number: NCT03656939

Locations: 🇨🇳
School of Public Health at Fudan University, Shanghai, China

A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers

Phase 1

Completed

Conditions: Phase 1

Interventions: Drug: PF-04965842
Drug: Midazolam

First Posted Date: 2018-08-27

Last Posted Date: 2020-03-23

Lead Sponsor: Pfizer

Target Recruit Count: 25

Registration Number: NCT03647670

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

Xeljanz Special Investigation for Long-term Use in UC Patients

Completed

Conditions: Ulcerative Colitis

First Posted Date: 2018-08-22

Last Posted Date: 2024-10-08

Lead Sponsor: Pfizer

Target Recruit Count: 2016

Registration Number: NCT03643211

Locations: 🇯🇵
Pfizer Local Country Office, Tokyo, Japan

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

Phase 3

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: Chemotherapy + avelumab followed by avelumab + talazoparib
Drug: Chemotherapy followed by talazoparib maintenance
Drug: Chemotherapy + bevacizumab followed by bevacizumab

First Posted Date: 2018-08-22

Last Posted Date: 2023-04-06

Lead Sponsor: Pfizer

Target Recruit Count: 79

Registration Number: NCT03642132

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇷🇺
Limited Liability Company "VitaMed" (LLC "VitaMed"), Moscow, Russian Federation
🇮🇪
Bon Secours Hospital, Cork, Ireland

and more 44 locations

Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

Phase 1

Completed

Conditions: Pneumococcal Infections

Interventions: Biological: multivalent pneumococcal conjugate formulation 1
Biological: Prevnar 13
Biological: multivalent pneumococcal conjugate formulation 2

First Posted Date: 2018-08-22

Last Posted Date: 2019-06-12

Lead Sponsor: Pfizer

Target Recruit Count: 104

Registration Number: NCT03642847

Locations: 🇺🇸
East-West Medical Research Institute, Honolulu, Hawaii, United States
🇺🇸
Collaborative Neuroscience Network, LLC., Long Beach, California, United States
🇺🇸
Clinilabs Drug Development Corporation, Eatontown, New Jersey, United States

A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Avelumab
Drug: Talazoparib
Drug: Binimetinib

First Posted Date: 2018-08-20

Last Posted Date: 2022-01-26

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT03637491

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States
🇺🇸
University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States

and more 13 locations

Drug Interaction Study Evaluating the Effect of Rifampin on PK and Safety of PF 04965842.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-04965842
Other: rifampin

First Posted Date: 2018-08-20

Last Posted Date: 2020-02-28

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT03637790

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.

Phase 1

Completed

Conditions: Dermatitis, Atopic

First Posted Date: 2018-08-16

Last Posted Date: 2019-01-30

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT03634345

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

Sedation Of Adult Patients Undergoing Gastrointestinal Endoscopy: A Network Meta-analysis

Completed

Conditions: Gastrointestinal Endoscopy
Sedation
Dexmedetomidine

Interventions: Drug: Midazolam/Propofol
Drug: Dexmedetomidine
Drug: Midazolam
Drug: Propofol

First Posted Date: 2018-08-15

Last Posted Date: 2023-04-06

Lead Sponsor: Pfizer

Target Recruit Count: 6963

Registration Number: NCT03632330

Locations: 🇰🇷
Pfizer Korea, Seoul, Korea, Republic of

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

Phase 3

Completed

Conditions: Dermatitis
Dermatitis, Atopic
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases

Interventions: Drug: Placebo
Drug: PF-04965842 200 mg
Drug: PF-04965842 100 mg

First Posted Date: 2018-08-13

Last Posted Date: 2021-09-20

Lead Sponsor: Pfizer

Target Recruit Count: 1235

Registration Number: NCT03627767

Locations: 🇺🇸
Owensboro Dermatology Associates, Owensboro, Kentucky, United States
🇺🇸
MediSearch Clinical Trials, Saint Joseph, Missouri, United States
🇺🇸
The University of Texas Health Science Center Houston, Houston, Texas, United States

and more 232 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy